Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone
Nature Methods has named spatial proteomics as its 'Method of the Year 2024', highlighting the transformative impact of this technology in biological research and medicine. Akoya Biosciences (Nasdaq: AKYA), a leader in spatial proteomics with 1300 installed instruments and nearly 1600 publications, celebrates this recognition.
Spatial proteomics enables scientists to map protein distribution within cells and tissues, providing insights into cellular mechanisms and disease progression. The company offers comprehensive solutions through its PhenoCycler®-Fusion platform for spatial discovery and PhenoImager® HT for translational applications.
Akoya's technology contributes significantly to global initiatives like the Human Tumor Atlas Network and HuBMAP, while powering multi-site collaborations such as the MANIFEST program. Their solutions range from multiplex immunofluorescence measuring 6-8 biomarkers to systems capable of profiling over 100 analytes in a single experiment.
Nature Methods ha nominato la proteomica spaziale come il 'Metodo dell'Anno 2024', evidenziando l'impatto trasformativo di questa tecnologia nella ricerca biologica e nella medicina. Akoya Biosciences (Nasdaq: AKYA), leader nella proteomica spaziale con 1300 strumenti installati e quasi 1600 pubblicazioni, celebra questo riconoscimento.
La proteomica spaziale consente agli scienziati di mappare la distribuzione delle proteine all'interno delle cellule e dei tessuti, fornendo approfondimenti sui meccanismi cellulari e sulla progressione delle malattie. L'azienda offre soluzioni complete attraverso la sua piattaforma PhenoCycler®-Fusion per la scoperta spaziale e PhenoImager® HT per applicazioni traslazionali.
La tecnologia di Akoya contribuisce in modo significativo a iniziative globali come il Human Tumor Atlas Network e HuBMAP, mentre supporta collaborazioni multi-sito come il programma MANIFEST. Le loro soluzioni variano dalla immunofluorescenza multipla che misura 6-8 biomarcatori a sistemi in grado di profilare oltre 100 analiti in un singolo esperimento.
Nature Methods ha nombrado a la proteómica espacial como el 'Método del Año 2024', destacando el impacto transformador de esta tecnología en la investigación biológica y la medicina. Akoya Biosciences (Nasdaq: AKYA), líder en proteómica espacial con 1300 instrumentos instalados y casi 1600 publicaciones, celebra este reconocimiento.
La proteómica espacial permite a los científicos mapear la distribución de proteínas dentro de células y tejidos, proporcionando información sobre los mecanismos celulares y la progresión de enfermedades. La empresa ofrece soluciones integrales a través de su plataforma PhenoCycler®-Fusion para el descubrimiento espacial y PhenoImager® HT para aplicaciones traslacionales.
La tecnología de Akoya contribuye significativamente a iniciativas globales como el Human Tumor Atlas Network y HuBMAP, mientras impulsa colaboraciones multi-sitio como el programa MANIFEST. Sus soluciones van desde inmunofluorescencia multiplex que mide de 6 a 8 biomarcadores hasta sistemas capaces de perfilar más de 100 analitos en un solo experimento.
Nature Methods는 공간 단백질체학을 '2024년의 방법'으로 선정하며, 이 기술이 생물학 연구와 의학에 미친 변혁적 영향을 강조했습니다. Akoya Biosciences (Nasdaq: AKYA)는 1300개의 설치된 장비와 거의 1600개의 출판물이 있는 공간 단백질체학의 선두주자로서 이 인정을 기념합니다.
공간 단백질체학은 과학자들이 세포 및 조직 내 단백질 분포를 매핑할 수 있도록 하여 세포 기전 및 질병 진행에 대한 통찰력을 제공합니다. 이 회사는 공간 발견을 위한 PhenoCycler®-Fusion 플랫폼 및 번역 애플리케이션을 위한 PhenoImager® HT를 통해 포괄적인 솔루션을 제공합니다.
Akoya의 기술은 Human Tumor Atlas Network 및 HuBMAP과 같은 글로벌 이니셔티브에 상당히 기여하며, MANIFEST 프로그램과 같은 다중 사이트 협업을 지원합니다. 그들의 솔루션은 6-8개의 바이오마커를 측정하는 다중 면역형광에서부터 단일 실험에서 100개 이상의 분석 물질을 프로파일링할 수 있는 시스템에 이르기까지 다양합니다.
Nature Methods a désigné la protéomique spatiale comme 'Méthode de l'Année 2024', mettant en avant l'impact transformateur de cette technologie dans la recherche biologique et la médecine. Akoya Biosciences (Nasdaq: AKYA), un leader dans le domaine de la protéomique spatiale avec 1300 instruments installés et près de 1600 publications, célèbre cette reconnaissance.
La protéomique spatiale permet aux scientifiques de cartographier la distribution des protéines au sein des cellules et des tissus, fournissant des informations sur les mécanismes cellulaires et la progression des maladies. L'entreprise propose des solutions complètes grâce à sa plateforme PhenoCycler®-Fusion pour la découverte spatiale et PhenoImager® HT pour des applications translationales.
La technologie d'Akoya contribue de manière significative aux initiatives mondiales comme le Human Tumor Atlas Network et HuBMAP, tout en soutenant des collaborations multisites telles que le programme MANIFEST. Leurs solutions varient de l'immunofluorescence multiplex mesurant 6 à 8 biomarqueurs à des systèmes capables de profiler plus de 100 analytes en une seule expérience.
Nature Methods hat die räumliche Proteomik als 'Methode des Jahres 2024' ausgewählt und hebt die transformative Wirkung dieser Technologie in der biologischen Forschung und Medizin hervor. Akoya Biosciences (Nasdaq: AKYA), ein führendes Unternehmen in der räumlichen Proteomik mit 1300 installierten Geräten und nahezu 1600 Publikationen, feiert diese Anerkennung.
Räumliche Proteomik ermöglicht es Wissenschaftlern, die Verteilung von Proteinen innerhalb von Zellen und Geweben zu kartieren, und bietet Einblicke in zelluläre Mechanismen und den Verlauf von Krankheiten. Das Unternehmen bietet umfassende Lösungen über seine Plattform PhenoCycler®-Fusion für räumliche Entdeckungen und PhenoImager® HT für translationale Anwendungen.
Die Technologie von Akoya leistet einen erheblichen Beitrag zu weltweiten Initiativen wie dem Human Tumor Atlas Network und HuBMAP und unterstützt Multi-Standort-Kooperationen wie das MANIFEST-Programm. Ihre Lösungen reichen von multiplex Immunfluoreszenz, die 6-8 Biomarker misst, bis hin zu Systemen, die in einem einzigen Experiment über 100 Analyten profilieren können.
- None.
- None.
MARLBOROUGH, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, announced that Nature Methods, one of the world’s leading scientific journals, has selected spatial proteomics as its prestigious “Method of the Year 2024”, recognizing the transformative potential of this approach in advancing biological research and medicine. As a global leader in spatial proteomics, with the industry’s largest installed base of 1300 instruments and nearly 1600 publications citing its technologies, Akoya celebrates this milestone as a testament to the technology’s impact and reaffirms its dedication to driving innovation in this rapidly evolving field.
Spatial proteomics provides scientists with the ability to map the spatial distribution of proteins within cells and tissues, revealing insights into cellular mechanisms, tissue architecture, and disease progression. Its applications span oncology, immunotherapy, neuroscience, drug development, and more, delivering unprecedented resolution and depth to biological research. Akoya offers complete end-to-end spatial proteomic solutions with instruments, reagents, software and services serving customers that span from discovery to diagnostics. The PhenoCycler®-Fusion is an ultrahigh-plex platform for spatial discovery while the PhenoImager® HT is a high-throughput platform for translational and clinical applications.
“At Akoya, we are proud to be at the forefront of spatial proteomics, revolutionizing how scientists understand complex biological systems,” said Brian McKelligon, CEO of Akoya Biosciences. “Spatial proteomics being recognized by Nature Methods underscores the pivotal role this method plays in driving scientific breakthroughs and further validates Akoya’s singular focus on driving continued advancement in our platforms for the betterment of our customers and ultimately patients.”
Customer and KOL Perspectives
Esteemed researchers and thought leaders in the scientific community have recognized the transformative potential of spatial proteomics and the contributions of Akoya Biosciences in this space:
Dr. Garry Nolan, Rachford and Carlota Harris Professor, Department of Pathology, Stanford University, Co-founder of Akoya Biosciences and Chair of Akoya’s Scientific Advisory Board commented:
“Spatial proteomics represents a paradigm shift in our ability to understand complex tissue architecture and cellular interactions in their native context. Akoya’s technology allows us to explore the intricate relationships between cells and their environments, unlocking insights that were previously unattainable and driving breakthroughs in both basic science and clinical applications.”
Dr. Arutha Kulasinghe, Associate Professor and Clinical-oMx Lab Head, Frazier Institute, University of Queensland commented:
“Integrating ultrahigh-plex spatial proteomics into our research has been revolutionary. The platforms offered by Akoya enable us to unravel protein networks with precision and scale, opening new avenues in studying immune response and disease pathways.”
Driving Innovation and Delivering Impact
Akoya has consistently led the evolution of spatial proteomics, delivering impactful contributions to the global research community. The company:
- Delivers a spectrum of solutions, ranging from multiplex immunofluorescence technologies measuring 6-8 biomarkers to ultrahigh-plex systems capable of profiling over 100 analytes in a single experiment.
- Contributes the largest data volume to flagship global initiatives such as the Human Tumor Atlas Network (HTAN) and HuBMAP (Human BioMolecular Atlas Program).
- Powers multi-site collaborations like the MANIFEST (Multiomic Analysis of Immunotherapy Features Evidencing Success and Toxicity) program, fostering standardization and scalability in high-impact research initiatives.
These innovations have enabled researchers worldwide to uncover critical insights into tissue biology, contributing to potential breakthroughs in areas such as precision medicine, biomarker discovery, and therapeutic development.
Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our expectations about the potential impact of spatial biology in advancing biological research and medicine, the potential of our products and services, our ability to develop, commercialize and achieve market acceptance of our current and planned products and services and other statements regarding our business strategies and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.
FAQ
What recognition did spatial proteomics receive from Nature Methods in 2024?
How many instruments and publications does Akoya Biosciences (AKYA) have as of 2024?
What are the main platforms offered by Akoya Biosciences (AKYA) for spatial proteomics?
How many biomarkers can Akoya's (AKYA) spatial proteomics technology measure?
